Cargando…

Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections

OBJECTIVES: The identification of the SARS-CoV-2 Omicron variants BA.1 and BA.2 immediately raised concerns about the efficacy of currently used monoclonal antibody therapies. Here, we analyzed the activity of Sotrovimab and Regdanvimab, which are used in clinics for treatment of moderate to severe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dichtl, Stefanie, Zaderer, Viktoria, Kozubowski, Viktoria, Abd El Halim, Hussam, Lafon, Eliott, Lanser, Lukas, Weiss, Günter, Lass-Flörl, Cornelia, Wilflingseder, Doris, Posch, Wilfried
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556863/ https://www.ncbi.nlm.nih.gov/pubmed/36250084 http://dx.doi.org/10.3389/fmed.2022.1005589

Ejemplares similares

ColdZyme® protects airway epithelia from infection with BA.4/5
por: Viktoria, Zaderer, et al.
Publicado: (2022)

Correction: ColdZyme® protects airway epithelia from infection with BA.4/5
por: Zaderer, Viktoria, et al.
Publicado: (2023)

Dexamethasone Creates a Suppressive Microenvironment and Promotes Aspergillus fumigatus Invasion in a Human 3D Epithelial/Immune Respiratory Model
por: Luvanda, Maureen K., et al.
Publicado: (2021)

Turning the World Upside-Down in Cellulose for Improved Culturing and Imaging of Respiratory Challenges within a Human 3D Model
por: Zaderer, Viktoria, et al.
Publicado: (2019)

Salivary antibodies induced by BA.4/BA.5-convalescence or bivalent booster Immunoglobulin vaccination protect against novel SARS-COV-2 variants of concern
por: Diem, Gabriel, et al.
Publicado: (2023)

Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5
por: Diem, Gabriel, et al.
Publicado: (2023)

Dexamethasone Promotes Aspergillus fumigatus Growth in Macrophages by Triggering M2 Repolarization via Targeting PKM2
por: Luvanda, Maureen K., et al.
Publicado: (2021)

Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees
por: Jäger, Michael, et al.
Publicado: (2022)

Salivary IgAs and Their Role in Mucosal Neutralization of SARS-CoV-2 Variants of Concern
por: Diem, Gabriel, et al.
Publicado: (2022)

Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation
por: Dichtl, Stefanie, et al.
Publicado: (2023)

Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern
por: Lafon, Eliott, et al.
Publicado: (2022)

Omicron subvariants illustrate reduced respiratory tissue penetration, cell damage and inflammatory responses in human airway epithelia
por: Zaderer, Viktoria, et al.
Publicado: (2023)

SARS-CoV-2–infected primary human airway epithelia illustrate mucus hypersecretion
por: Posch, Wilfried, et al.
Publicado: (2021)

Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients
por: Lafon, Eliott, et al.
Publicado: (2021)

Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants
por: Jäger, Michael, et al.
Publicado: (2023)

Tixagevimab + Cilgavimab: First Approval
por: Keam, Susan J.
Publicado: (2022)

Serum Neutralization Against SARS-CoV-2 Variants Is Heterogenic and Depends on Vaccination Regimen
por: Jäger, Michael, et al.
Publicado: (2022)

Role of Complement Receptors (CRs) on DCs in Anti-HIV-1 Immunity
por: Posch, Wilfried, et al.
Publicado: (2020)

Tixagevimab and cilgavimab for COVID-19 prophylaxis
Publicado: (2022)

Tixagevimab/ Cilgavimab Outcomes Among Patients with Immunodeficiency
por: Sullivan, Juliana
Publicado: (2023)

GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events
por: Zaderer, Viktoria, et al.
Publicado: (2023)

C5aR inhibition of nonimmune cells suppresses inflammation and maintains epithelial integrity in SARS-CoV-2–infected primary human airway epithelia
por: Posch, Wilfried, et al.
Publicado: (2021)

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
por: Levin, Myron J., et al.
Publicado: (2022)

A case of prolonged COVID‐19 treated with tixagevimab/cilgavimab
por: Shimizu, Takahiro, et al.
Publicado: (2023)

Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
por: Chen, Benjamin, et al.
Publicado: (2023)

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
por: Yang, Jinyoung, et al.
Publicado: (2023)

Real-World Effectiveness of Tixagevimab and Cilgavimab (Evusheld) in Patients With Hematological Malignancies
por: Ocon, Anthony J., et al.
Publicado: (2022)

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi
por: Zamprogna, Giulia, et al.
Publicado: (2023)

SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab
por: Stiasny, Karin, et al.
Publicado: (2022)

P80 Natural Essence Exerts Efficient Anti-HIV-1- as Well as Adjuvant Effects in DCs
por: Zaderer, Viktoria, et al.
Publicado: (2021)

ColdZyme Maintains Integrity in SARS-CoV-2-Infected Airway Epithelia
por: Posch, W., et al.
Publicado: (2021)

Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients
por: Aqeel, Faten, et al.
Publicado: (2022)

Cardiac and vascular serious adverse events following tixagevimab–cilgavimab – Author's reply
por: Maselkar, Sheetal, et al.
Publicado: (2023)

Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab
por: Solera, Javier T, et al.
Publicado: (2023)

P1574: EFFICACY AND SAFETY OF TIXAGEVIMAB AND CILGAVIMAB (EVUSHELD) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
por: Aleshina (Gavrilina), Olga, et al.
Publicado: (2023)

1339. Effects of Tixagevimab-Cilgavimab in Clinical Practice is Consistent with Preliminary Neutralization Studies
por: Dluzynski, Daniela, et al.
Publicado: (2023)

INCIDENCE OF COVID-19 INFECTIONS IN ADULTS WITH PRIMARY IMMUNODEFICIENCY AFTER RECEIVING TIXAGEVIMAB AND CILGAVIMAB
por: Johnson, S., et al.
Publicado: (2022)

Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases
por: Otiniano, Armelle, et al.
Publicado: (2022)

Tixagevimab and Cilgavimab (Evusheld – AstraZeneca) efficacy in preventing COVID infection in immunocompromised patients
por: Miot, Christelle, et al.
Publicado: (2023)

Safety and immunogenicity of cilgavimab-tixagevimab for COVID-19 pre-exposure prophylaxis in immunocompromised patients
por: Fernández-Prada, María, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3s66rgkfg5m1rt38siouf3oksk